Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions

Crit Rev Oncol Hematol. 2016 Jan:97:328-34. doi: 10.1016/j.critrevonc.2015.08.002. Epub 2015 Aug 8.

Abstract

The significant improvement of cancer treatments entailed a longer life in cancer survivors and raised expectations for higher quality of life with minimized long-term toxicity. Infertility and gonadal dysfunction are adverse effects of anticancer therapy or may be related to specific tumors. In female cancer survivors, premature ovarian failure is common after antineoplastic treatments resulting in infertility and other morbidities related to oestrogen deficiency such as osteoporosis. In male cancer survivors, infertility and persistent a zoospermia is a more common long-term adverse effect than hypogonadism because germ cells are more sensitive to chemotherapy and radiotherapy than leydig cells. Gonadal toxicity and compromise of reproductive functions will be more efficiently prevented and treated if addressed before treatment initiation. This review focuses on these issues in young cancer survivors of childbearing age, where methods of protecting or restoring endocrine function and fertility need to be considered.

Keywords: Anticancer treatment; Cryopreservation; Fertility preservation; Gonadotoxicity; Infertility.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Female
  • Fertility / drug effects*
  • Fertility / radiation effects*
  • Fertility Preservation / methods*
  • Humans
  • Infertility / etiology
  • Male
  • Neoplasms / therapy*
  • Quality of Life
  • Radiotherapy / adverse effects
  • Survivors
  • Urogenital System / drug effects
  • Urogenital System / radiation effects

Substances

  • Antineoplastic Agents